Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Takeda Pharmaceutical Company Limited is a drug manufacturers-specialty & generic business based in the US. Takeda Pharmaceutical shares (TAK) are listed on the NYSE and all prices are listed in US Dollars. Takeda Pharmaceutical employs 47,495 staff and has a market cap (total outstanding shares value) of USD$54.1 billion.
Since the stock market crash in March caused by coronavirus, Takeda Pharmaceutical's share price has had significant negative movement.
Its last market close was USD$16.67, which is 11.28% down on its pre-crash value of USD$18.79 and 34.11% up on the lowest point reached during the March crash when the shares fell as low as USD$12.43.
If you had bought USD$1,000 worth of Takeda Pharmaceutical shares at the start of February 2020, those shares would have been worth USD$689.01 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$861.01.
|Latest market close||USD$16.67|
|52-week range||USD$12.43 - USD$20.42|
|50-day moving average||USD$18.3176|
|200-day moving average||USD$17.8818|
|Wall St. target price||USD$23.59|
|Dividend yield||USD$0.85 (4.83%)|
|Earnings per share (TTM)||USD$0.8115|
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-15)||-4.42%|
|1 month (2020-12-23)||-8.81%|
|3 months (2020-10-23)||0.06%|
|6 months (2020-07-23)||-3.92%|
|1 year (2020-01-23)||-16.73%|
|2 years (2019-01-23)||-16.44%|
|3 years (2018-01-23)||-44.58%|
|5 years (2016-01-22)||-29.78%|
Valuing Takeda Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Takeda Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Takeda Pharmaceutical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 22x. In other words, Takeda Pharmaceutical shares trade at around 22x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Takeda Pharmaceutical's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.1176. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Takeda Pharmaceutical's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Gross profit TTM||USD$2,201.5 billion|
|Return on assets TTM||1.2%|
|Return on equity TTM||1.18%|
|Market capitalisation||USD$54.1 billion|
TTM: trailing 12 months
There are currently 7.6 million Takeda Pharmaceutical shares held short by investors – that's known as Takeda Pharmaceutical's "short interest". This figure is 15.5% up from 6.6 million last month.
There are a few different ways that this level of interest in shorting Takeda Pharmaceutical shares can be evaluated.
Takeda Pharmaceutical's "short interest ratio" (SIR) is the quantity of Takeda Pharmaceutical shares currently shorted divided by the average quantity of Takeda Pharmaceutical shares traded daily (recently around 1.9 million). Takeda Pharmaceutical's SIR currently stands at 4.07. In other words for every 100,000 Takeda Pharmaceutical shares traded daily on the market, roughly 4070 shares are currently held short.
However Takeda Pharmaceutical's short interest can also be evaluated against the total number of Takeda Pharmaceutical shares, or, against the total number of tradable Takeda Pharmaceutical shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Takeda Pharmaceutical's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Takeda Pharmaceutical shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Takeda Pharmaceutical shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Takeda Pharmaceutical.
This vacation-rental giant has finally gone public. Learn how to invest in Airbnb in Ireland.
Steps to owning and managing Vaxart shares from Ireland.
Steps to owning and managing Sinovac Biotech Ltd shares from Ireland.
Steps to owning and managing Mesoblast shares from Ireland.
Steps to owning and managing Inovio Pharmaceuticals shares from Ireland.
Steps to owning and managing Heat Biologics shares from Ireland.
Steps to owning and managing CytoDyn shares from Ireland.
Steps to owning and managing Cynata Therapeutics shares from Ireland.
Steps to owning and managing BioNTech shares from Ireland.
Steps to owning and managing Atomo Diagnostics shares from Ireland.
finder.com.au is one of Australia's leading comparison websites. We compare from a wide set of banks, insurers and product issuers. We value our editorial independence and follow editorial guidelines.
finder has access to track details from the product issuers listed on our sites. Although we provide information on the products offered by a wide range of issuers, we don't cover every available product or service.
Please note that the information published on our site should not be construed as personal advice and does not consider your personal needs and circumstances. While our site will provide you with factual information and general advice to help you make better decisions, it isn't a substitute for professional advice. You should consider whether the products or services featured on our site are appropriate for your needs. If you're unsure about anything, seek professional advice before you apply for any product or commit to any plan.
Products marked as 'Promoted' or 'Advertisement' are prominently displayed either as a result of a commercial advertising arrangement or to highlight a particular product, provider or feature. Finder may receive remuneration from the Provider if you click on the related link, purchase or enquire about the product. Finder's decision to show a 'promoted' product is neither a recommendation that the product is appropriate for you nor an indication that the product is the best in its category. We encourage you to use the tools and information we provide to compare your options.
Where our site links to particular products or displays 'Go to site' buttons, we may receive a commission, referral fee or payment when you click on those buttons or apply for a product.
When products are grouped in a table or list, the order in which they are initially sorted may be influenced by a range of factors including price, fees and discounts; commercial partnerships; product features; and brand popularity. We provide tools so you can sort and filter these lists to highlight features that matter to you.
We try to take an open and transparent approach and provide a broad-based comparison service. However, you should be aware that while we are an independently owned service, our comparison service does not include all providers or all products available in the market.
Some product issuers may provide products or offer services through multiple brands, associated companies or different labelling arrangements. This can make it difficult for consumers to compare alternatives or identify the companies behind the products. However, we aim to provide information to enable consumers to understand these issues.
Providing or obtaining an estimated insurance quote through us does not guarantee you can get the insurance. Acceptance by insurance companies is based on things like occupation, health and lifestyle. By providing you with the ability to apply for a credit card or loan, we are not guaranteeing that your application will be approved. Your application for credit products is subject to the Provider's terms and conditions as well as their application and lending criteria.